Glimepiride

Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. The selected label says not to use for type 1 diabetes or diabetic ketoacidosis because it is ineffective in these settings. Pediatric use is not recommended because of weight gain and hypoglycemia effects.

Glimepiride lowers glucose through pancreatic insulin release; it requires individualized selection and follow-up. The selected label does not establish macrovascular risk reduction for glimepiride. Its legacy broader statement about all antidiabetic drugs should not be generalized into a current class-wide conclusion; this profile makes only the glimepiride-specific claim. Fixed glimepiride combinations, treatment algorithms and cardiovascular-benefit comparisons are outside this profile.

Take with breakfast or the first main meal of the day.

When switching from longer-half-life sulfonylureas such as chlorpropamide, overlapping effects may last 1–2 weeks; increase observation for hypoglycemia. Starting or stopping other glucose-lowering/interaction-prone medicines can require dose adjustment and closer glucose checks. Low calorie intake, prolonged exercise, alcohol, illness or organ-function changes require reassessment rather than an automatic dose increase.

Renal impairment: start 1 mg daily and titrate cautiously; the label gives no universal eGFR dose ceiling or dialysis-based regimen. Reduced metabolite elimination contributes to risk. Hepatic PK is inadequately evaluated, and hepatic impairment increases susceptibility to hypoglycemia; select/titrate cautiously with clinician review rather than inventing a fixed percentage reduction. Debilitated, malnourished or adrenal/pituitary-impaired patients also need conservative assessment.

Keep administration linked to the first main meal. The selected label does not provide a universal missed-dose algorithm; arrange individualized instructions, especially when meals are missed, rather than doubling later. In pregnancy, discontinue at least 2 weeks before expected delivery under a replacement glycemic-management plan to reduce neonatal hypoglycemia risk.

History of hypersensitivity to glimepiride, product ingredients or sulfonamide derivatives under the selected U.S. label. Type 1 diabetes and DKA are separately listed as ineffective-use limitations. Assess the actual allergy history and label rather than assuming all formulations remove the sulfonamide restriction.

The selected current U.S. standalone glimepiride label has no boxed warning. The sulfonylurea cardiovascular-mortality warning appears in section 5.4. Do not import the heart-failure boxed warning from a glimepiride/pioglitazone combination product into standalone glimepiride.

Common reported trial effects include hypoglycemia, dizziness, weakness, headache and nausea; weight gain can occur. Postmarketing reports include severe allergy/skin reactions, liver injury, hemolysis, leukopenia/agranulocytosis, thrombocytopenia/aplastic anemia, photosensitivity and hyponatremia/SIADH, with uncertain incidence. Overdose can cause prolonged/recurrent severe hypoglycemia. Obtain emergency/Poison Help care (U.S. 1-800-222-1222); mild conscious episodes can use oral glucose, while seizure/coma requires clinician-administered IV glucose or glucagon and continued observation.

Selected examples below do not replace full medicine reconciliation.

This label supplies no universal blood-level monitoring target or laboratory-interference algorithm. Use glucose/glycemic trends and clinical symptoms; investigate unexplained anemia, liver abnormalities or low sodium rather than assuming every abnormal result is a routine drug effect.

Limited pregnancy data have not identified a major malformation/miscarriage signal, but sulfonylureas cross the placenta and can cause neonatal hypoglycemia and other adverse effects. Discontinue ≥ 2 weeks before expected delivery under clinician supervision and observe exposed newborns for hypoglycemia/respiratory distress. Poorly controlled diabetes also harms mother and fetus. Human milk transfer is unknown; animal milk transfer occurs. Weigh maternal need and breastfeeding, and monitor breastfed infants for poor feeding, excessive sleepiness, jitters, cyanosis, apnea, hypothermia or seizures.

Pediatric glimepiride is not recommended because of weight gain and hypoglycemia, despite trials in ages 8–17; trial doses are not approved pediatric directions. Older adults should start 1 mg daily and titrate cautiously, considering renal impairment and difficult-to-recognize lows; an absence of overall trial differences does not eliminate individual sensitivity.

Renal impairment requires 1 mg initial dosing and cautious follow-up, with reduced metabolite elimination. Hepatic PK is not adequately established; hepatic, adrenal/pituitary impairment, malnutrition or debility can increase low-glucose susceptibility. Do not infer a dialysis schedule or fixed hepatic reduction from the PK studies.

Binding to the pancreatic beta-cell sulfonylurea receptor closes ATP-sensitive potassium channels and stimulates insulin release. The drug does not replace absent insulin in type 1 diabetes or acute DKA therapy.

Time course

Peak concentrations and single-dose maximal glucose effect occur around 2–3 hours. Meals modestly reduce peak/exposure; label still directs administration with breakfast/first main meal.

Distribution

Very high protein binding (> 99.5%).

Metabolism

CYP2C9 contributes to M1 formation, then M2. M2 is inactive; clinically meaningful human M1 glucose effects remain uncertain.

Elimination / organ changes

Radiolabel mainly recovered in urine (~60%) and feces (~40%) as metabolites; renal impairment reduces metabolite elimination. Hepatic PK is inadequately studied.

Review glucose results, glycemic progress, low-glucose episodes, meal intake, weight, kidney/liver disease and interacting drugs during titration and follow-up. Increase glucose checks after dose/drug changes, reduced intake or illness; periodic HbA1c assessment belongs to the individualized diabetes plan. Evaluate new anemia/G6PD concerns, jaundice, severe rash or possible low-sodium symptoms clinically. No single laboratory interval or universal target is mandated by this label.

Take with breakfast or the first main meal, follow the prescribed dose and ask for missed-meal/missed-dose instructions. Know low-glucose symptoms and oral treatment only when safely able to swallow; teach caregivers the emergency rescue plan. Carry rescue supplies and consider driving risk. Discuss alcohol and all new/stopped medicines. Seek urgent care for severe allergy, rash, seizure or unconsciousness. Report pregnancy promptly; nursing infants require the stated hypoglycemia surveillance.

Aurobindo glimepiride 1 mg: pink oblong uncoated bisected tablet marked X / 76; example 100-count bottle NDC 65862-579-01. Color/imprint descriptions apply to this manufacturer only.

Store at 20–25°C and dispense in a well-closed container with a safety closure. Keep away from children; accidental ingestion can cause recurrent hypoglycemia. Keep the prescribed dose and exact tablet strength clear when more than one tablet is needed.